Skip to main content
Targeted Therapies for Advanced Non-Small Cell Lung Cancer
  • Xiaojuan Ai
  • Xialing Guo
  • Jun Wang
  • Andreea L Stancu
  • Patrick M N Joslin
  • Dianzheng Zhang, Philadelphia College of Osteopathic Medicine
  • Shudong Zhu
Document Type
Publication Date

Lung cancer is a serious health problem and the leading cause of cancer death worldwide, due to its high incidence and mortality. 85% of lung cancers are represented by the non-small cell lung cancer (NSCLC). Traditional chemotherapy has been the main treatment option in NSCLC. However, it is often associated with limited efficacy and overall poor patient survival. In recent years, molecular targeting has achieved great progress in therapeutic treatment of cancer and plays a crucial role in the current clinical treatment of NSCLC, due to enhanced efficacy on cancer tissues and reduced toxicity for normal tissues. In this review, we summarize the current targeting treatment of NSCLC, including inhibition of the epidermal growth factor receptor (EGFR), phosphatidylinositol 3-kinase (PI3Ks), mechanistic target of rapamycin (mTOR), epidermal growth factor receptor 2 (ErbB2), vascular epidermal growth factor receptor (VEGFR), kirsten human rat sarcoma protein (KRAS), mesenchymal-epithelial transition factor or hepatocyte growth factor receptor (c-MET), anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma viral oncogene homolog B (BRAF). This article may serve as a guide to clinicians and researchers alike by assisting in making therapeutic decisions. Challenges of acquired drug resistance targeted therapy and imminent newer treatment modalities against NSCLC are also discussed.

PubMed ID

This article was published in Oncotarget, Volume 9, pages 37589-37607.

The published version is available at

Copyright © 2018. CC-BY 3.0

Citation Information
Xiaojuan Ai, Xialing Guo, Jun Wang, Andreea L Stancu, et al.. "Targeted Therapies for Advanced Non-Small Cell Lung Cancer" Oncotarget Vol. 9 (2018) p. 37589 - 37607
Available at: